{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T21:54:56Z","timestamp":1782251696928,"version":"3.54.5"},"reference-count":38,"publisher":"The Endocrine Society","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,12,1]]},"abstract":"<jats:sec>\n                  <jats:title>Context:<\/jats:title>\n                  <jats:p>Congenital hyperinsulinism (CHI) is the most common cause of persistent hypoglycemia in neonates and infants. In medically unresponsive CHI, subtotal pancreatectomy is performed to achieve euglycemia with consequent diabetes in later life. Sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been reported to obviate the need for pancreatectomy, but experience is limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective:<\/jats:title>\n                  <jats:p>We have investigated the efficacy and adverse effect profile of mTOR inhibitors in the treatment of severe CHI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design, Setting, and Patients:<\/jats:title>\n                  <jats:p>This was an observational review of 10 severe CHI patients treated with mTOR inhibitors, in France and the United Kingdom, with the intention of achieving glycemic control without pancreatectomy. Safety information was recorded.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measure(s):<\/jats:title>\n                  <jats:p>We examined whether mTOR inhibitors achieved glycemic control, fasting tolerance, and weaning of supportive medical therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>mTOR inhibition achieved euglycemia, fasting tolerance, and reduced medical therapy in only three patients (30%). Triglyceride levels were elevated in five patients (50%). One child required a blood transfusion for anemia, four had stomatitis, two had sepsis, one developed varicella zoster, and two patients developed gut dysmotility in association with exocrine pancreatic insufficiency. In silico analysis of transcriptome arrays from CHI patients revealed no significant association between mTOR signaling and disease. Pancreatic tissue from two patients who did not respond to sirolimus showed no reduction in cell proliferation, further suggesting that mTOR signaling did not down-regulate proliferation in the CHI pancreas.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion:<\/jats:title>\n                  <jats:p>mTOR inhibitor treatment is associated with very limited success and must be used with caution in children with severe CHI.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jc.2016-2711","type":"journal-article","created":{"date-parts":[[2016,10,3]],"date-time":"2016-10-03T18:42:08Z","timestamp":1475520128000},"page":"4719-4729","source":"Crossref","is-referenced-by-count":51,"title":["mTOR Inhibitors for the Treatment of Severe Congenital Hyperinsulinism: Perspectives on Limited Therapeutic Success"],"prefix":"10.1210","volume":"101","author":[{"given":"Marie","family":"Szymanowski","sequence":"first","affiliation":[{"name":"Department of Pediatrics (M.S.), Centre Hospitalier Universitaire Estaing, 63003 Clermont-Ferrand Cedex 1, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Salomon","family":"Estebanez","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology (M.S.E., R.P., I.B.), Royal Manchester Children\u2019s Hospital, Manchester M13 9WL, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Padidela","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology (M.S.E., R.P., I.B.), Royal Manchester Children\u2019s Hospital, Manchester M13 9WL, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology (M.S.E., R.P., I.B.), Royal Manchester Children\u2019s Hospital, Manchester M13 9WL, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Mosinska","sequence":"additional","affiliation":[{"name":"Faculty of Life Science (B.H., K.M., A.S., M.J.D.), University of Manchester, Manchester M13 9PL, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Stevens","sequence":"additional","affiliation":[{"name":"Faculty of Life Science (B.H., K.M., A.S., M.J.D.), University of Manchester, Manchester M13 9PL, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Damaj","sequence":"additional","affiliation":[{"name":"Department of Pediatrics (L.D., F.P.-L.B., E.L.), Sud Hospital, 35203 Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Pihan-Le Bars","sequence":"additional","affiliation":[{"name":"Department of Pediatrics (L.D., F.P.-L.B., E.L.), Sud Hospital, 35203 Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Lascouts","sequence":"additional","affiliation":[{"name":"Department of Pediatrics (L.D., F.P.-L.B., E.L.), Sud Hospital, 35203 Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Reynaud","sequence":"additional","affiliation":[{"name":"Department of Pediatrics (R.R., C.F.), Timone Hospital, 13385 Marseille Cedex 5, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Department of Pediatrics (R.R., C.F.), Timone Hospital, 13385 Marseille Cedex 5, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Bansept","sequence":"additional","affiliation":[{"name":"Metabolism Unit (C.B., P.d.L., J.-B.A.), Necker-Enfants Malades Hospital, Assistance Publique-H\u00f4pitaux de Paris, 75743 Paris Cedex 15, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"de Lonlay","sequence":"additional","affiliation":[{"name":"Metabolism Unit (C.B., P.d.L., J.-B.A.), Necker-Enfants Malades Hospital, Assistance Publique-H\u00f4pitaux de Paris, 75743 Paris Cedex 15, France"},{"name":"Imagine-Genetic Disease Institute (P.d.L.), 75015 Paris, France; Paris Descartes University (P.d.L.), 75270 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Saint-Martin","sequence":"additional","affiliation":[{"name":"Department of Genetics (C.S.-M.), Assistance Publique-H\u00f4pitaux de Paris Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Pierre et Marie Curie University, 75013 Paris Cedex 13, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Dunne","sequence":"additional","affiliation":[{"name":"Faculty of Life Science (B.H., K.M., A.S., M.J.D.), University of Manchester, Manchester M13 9PL, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indraneel","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology (M.S.E., R.P., I.B.), Royal Manchester Children\u2019s Hospital, Manchester M13 9WL, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Arnoux","sequence":"additional","affiliation":[{"name":"Metabolism Unit (C.B., P.d.L., J.-B.A.), Necker-Enfants Malades Hospital, Assistance Publique-H\u00f4pitaux de Paris, 75743 Paris Cedex 15, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2016,10,3]]},"reference":[{"key":"2020071614212140700_B1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1530\/eje.0.1490043","article-title":"Long-term follow-up of 114 patients with congenital hyperinsulinism","volume":"149","author":"Meissner","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"2020071614212140700_B2","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1542\/peds.107.3.476","article-title":"Neurologic outcomes of 90 neonates and infants with persistent hyperinsulinemic hypoglycemia","volume":"107","author":"Menni","year":"2001","journal-title":"Pediatrics"},{"key":"2020071614212140700_B3","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1210\/jc.2013-2094","article-title":"Clinical presentation and management of children with diffuse and focal hyperinsulinism: a review of 223 cases","volume":"98","author":"Lord","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614212140700_B4","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jpeds.2015.03.057","article-title":"Recommendations from the Pediatric Endocrine Society for evaluation and management of persistent hypoglycemia in neonates, infants, and children","volume":"167","author":"Thornton","year":"2015","journal-title":"J Pediatr"},{"key":"2020071614212140700_B5","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1007\/s00247-012-2459-2","article-title":"Diagnostic performance of fluorine-18-dihydroxyphenylalanine positron emission tomography in diagnosing and localizing the focal form of congenital hyperinsulinism: a meta-analysis","volume":"42","author":"Treglia","year":"2012","journal-title":"Pediatr Radiol"},{"key":"2020071614212140700_B6","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11307-012-0572-0","article-title":"The value of radiologic interventions and 18F-DOPA PET in diagnosing and localizing focal congenital hyperinsulinism: systematic review and meta-analysis","volume":"15","author":"Blomberg","year":"2013","journal-title":"Mol Imaging Biol"},{"key":"2020071614212140700_B7","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2337\/dc11-1296","article-title":"Glucose metabolism in 105 children and adolescents after pancreatectomy for congenital hyperinsulinism","volume":"35","author":"Beltrand","year":"2012","journal-title":"Diabetes Care"},{"key":"2020071614212140700_B8","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1310967","article-title":"Sirolimus therapy in infants with severe hyperinsulinemic hypoglycemia","volume":"370","author":"Senniappan","year":"2014","journal-title":"N Engl J Med"},{"key":"2020071614212140700_B9","first-page":"548","article-title":"Genomic and morphoproteomic correlates implicate the IGF-1\/mTOR\/Akt pathway in the pathogenesis of diffuse congenital hyperinsulinism","volume":"9","author":"Senniappan","year":"2016","journal-title":"Int J Clin Exp Pathol"},{"key":"2020071614212140700_B10","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4161\/cbt.365","article-title":"The molecular target of rapamycin (mTOR) as a therapeutic target against cancer","volume":"2","author":"Mita","year":"2003","journal-title":"Cancer Biol Ther"},{"key":"2020071614212140700_B11","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/petr.12261","article-title":"Three-year safety and efficacy of everolimus and low-dose cyclosporine in de novo pediatric kidney transplant patients","volume":"18","author":"Ferraresso","year":"2014","journal-title":"Pediatr Transplant"},{"key":"2020071614212140700_B12","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/neuonc\/not150","article-title":"Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas","volume":"16","author":"Karajannis","year":"2014","journal-title":"Neuro Oncol"},{"key":"2020071614212140700_B13","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/ana.23960","article-title":"Everolimus treatment of refractory epilepsy in tuberous sclerosis complex","volume":"74","author":"Krueger","year":"2013","journal-title":"Ann Neurol"},{"key":"2020071614212140700_B14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2147\/BTT.S25095","article-title":"Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex","volume":"7","author":"Franz","year":"2013","journal-title":"Biol Targets Ther"},{"key":"2020071614212140700_B15","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1210\/jc.2009-0788","article-title":"Successful control of intractable hypoglycemia using rapamycin in an 86-year-old man with a pancreatic insulin-secreting islet cell tumor and metastases","volume":"94","author":"Bourcier","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614212140700_B16","doi-asserted-by":"crossref","first-page":"iii18","DOI":"10.1093\/ndt\/gfl300","article-title":"Everolimus in clinical practice\u2014renal transplantation","volume":"21","author":"Pascual","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"2020071614212140700_B17","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00467-013-2459-y","article-title":"Long-term side effects of treatment with mTOR inhibitors in children after renal transplantation","volume":"28","author":"Kranz","year":"2013","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"key":"2020071614212140700_B18","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.transproceed.2006.01.044","article-title":"Side effects of sirolimus","volume":"38","author":"Merkel","year":"2006","journal-title":"Transplant Proc"},{"key":"2020071614212140700_B19","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1016\/j.transproceed.2009.07.094","article-title":"Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion","volume":"41","author":"Sayin","year":"2009","journal-title":"Transplant Proc"},{"key":"2020071614212140700_B20","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1517\/14740338.2013.752814","article-title":"Adverse events associated with mTOR inhibitors","volume":"12","author":"Pallet","year":"2013","journal-title":"Expert Opin Drug Saf"},{"key":"2020071614212140700_B21","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1210\/jc.2010-3032","article-title":"Morphological mosaicism of the pancreatic islets: a novel anatomopathological form of persistent hyperinsulinemic hypoglycemia of infancy","volume":"96","author":"Sempoux","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614212140700_B22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/j.sempedsurg.2010.10.010","article-title":"Morphologic analysis of focal and diffuse forms of congenital hyperinsulinism","volume":"20","author":"Rahier","year":"2011","journal-title":"Semin Pediatr Surg"},{"key":"2020071614212140700_B23","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.2337\/db14-1202","article-title":"Altered phenotype of \u03b2-cells and other pancreatic cell lineages in patients with diffuse congenital hyperinsulinism in infancy caused by mutations in the ATP-sensitive K-channel","volume":"64","author":"Salisbury","year":"2015","journal-title":"Diabetes"},{"key":"2020071614212140700_B24","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/cge.12428","article-title":"Monoallelic ABCC8 mutations are a common cause of diazoxide-unresponsive diffuse form of congenital hyperinsulinism","volume":"87","author":"Saint-Martin","year":"2015","journal-title":"Clin Genet"},{"key":"2020071614212140700_B25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1365-2265.2007.02847.x","article-title":"Complex ABCC8 DNA variations in congenital hyperinsulinism: lessons from functional studies","volume":"67","author":"Muzyamba","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071614212140700_B26","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1530\/EJE-12-0673","article-title":"Clinical and molecular characterisation of 300 patients with congenital hyperinsulinism","volume":"168","author":"Kapoor","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2020071614212140700_B27","doi-asserted-by":"crossref","first-page":"E355","DOI":"10.1210\/jc.2012-2169","article-title":"Genotype and phenotype correlations in 417 children with congenital hyperinsulinism","volume":"98","author":"Snider","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614212140700_B28","doi-asserted-by":"crossref","first-page":"P123","DOI":"10.1186\/1687-9856-2015-S1-P123","article-title":"Sirolimus treatment of severe congenital hyperinsulinism","volume":"2015","author":"Amato","year":"2015","journal-title":"Int J Pediatr Endocrinol"},{"key":"2020071614212140700_B29","first-page":"86","article-title":"Efficacity and safety of sirolimus (mTOR inhibitor) in two patients with diazoxide-unresponsive hyperinsulinemic hypoglycemia","volume":"7","author":"Kara","year":"2015","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"2020071614212140700_B30","first-page":"695","article-title":"Sirolimus therapy in a patient with severe hyperinsulinaemic hypoglycaemia due to a compound heterozygous ABCC8 gene mutation","volume":"28","author":"Shah","year":"2014","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2020071614212140700_B31","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1542\/peds.2015-1132","article-title":"Sirolimus therapy in congenital hyperinsulinism: a successful experience beyond infancy","volume":"136","author":"Minute","year":"2015","journal-title":"Pediatrics"},{"key":"2020071614212140700_B32","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1542\/peds.2014-4200","article-title":"Severe hyperinsulinemic hypoglycemia in a neonate: response to sirolimus therapy","volume":"136","author":"M\u00e9der","year":"2015","journal-title":"Pediatrics"},{"key":"2020071614212140700_B33","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1530\/EJE-12-1101","article-title":"Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia","volume":"168","author":"Bernard","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"2020071614212140700_B34","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1515\/jpem-2015-0094","article-title":"Efficacy and safety of sirolimus in a neonate with persistent hypoglycaemia following near-total pancreatectomy for hyperinsulinaemic hypoglycaemia","volume":"28","author":"Abraham","year":"2015","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2020071614212140700_B35","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.2337\/db09-1324","article-title":"Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue","volume":"59","author":"Houde","year":"2010","journal-title":"Diabetes"},{"issue":"10","key":"2020071614212140700_B36","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1007\/s00125-006-0374-5","article-title":"The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells","volume":"49","author":"Bussiere","year":"2006","journal-title":"Diabetologia"},{"key":"2020071614212140700_B37","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2147\/DMSO.S19027","article-title":"New onset diabetes after transplantation (NODAT): an overview","volume":"4","author":"Pham","year":"2011","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"key":"2020071614212140700_B38","doi-asserted-by":"crossref","first-page":"R79","DOI":"10.1530\/JME-13-0112","article-title":"Network analysis: a new approach to study endocrine disorders","volume":"52","author":"Stevens","year":"2014","journal-title":"J Mol Endocrinol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/101\/12\/4719\/10528814\/jcem4719.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/101\/12\/4719\/10528814\/jcem4719.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T02:03:26Z","timestamp":1594951406000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/101\/12\/4719\/2765054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,3]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2016-2711","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,3]]}}}